奇正藏藥(002287.SZ):在呼吸系統、消化系統等多個治療領域都擁有適合招商市場的優勢產品
格隆匯11月15日丨奇正藏藥(002287.SZ)於2024年11月14日接受特定對象調研時表示,公司擁有141個藥品批准文號,產品覆蓋骨科、神經科、皮科、婦科、兒科、呼吸科、消化科、心腦血管科等多個藏醫特色治療領域;招商可以發掘並激活公司更多的優質產品,通過精準的市場開發策略,為這些產品注入新的活力。針對不同產品的不同特性,公司制定細緻的招商方案。公司在呼吸系統、消化系統等多個治療領域都擁有適合招商市場的優勢產品,為公司招商業務的拓展奠定了較好的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.